External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology Macula Society 2023
Roche and Genentech at

Macula Society 2023

February 15 - February 18
Miami, USA
maculasociety.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
09:21 AM
Duration 9mins Fontainebleau
Treatment Patterns and Outcomes With Anti-VEGF Therapy for BRVO and CRVO: An Analysis of the Vestrum Database
Ip M, Fekrat S, Modi Y, Gibson K, Arrisi P, Liu Y, Fenech M, Boucher N, Chi G
Ophthalmology | Retinal Vein Occlusion

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:38 AM
Duration 4mins Fontainebleau
Efficacy and Safety of Faricimab in Macular Edema Due to Retinal Vein Occlusion: 24-Week Results From the Phase 3 BALATON and COMINO Trials
Khanani A, Paris L, Abreu F, Basu K, Arrisi P, Haskova Z, Liu Y, Willis J, Eden C, Kotecha A
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:53 AM
Duration 9mins Fontainebleau
Durable Vision Gains and Greater Fluid Control With Extended Faricimab Dosing Up to Every 16-Weeks Over 2 Years of Phase 3 YOSEMITE and RHINE Trials in DME
Weng C, Steinle N, Goldberg R, Jaffe G, Gerendes B, Camino A, Tang Y, Haskova Z
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:20 AM
Duration 9mins Fontainebleau
Clinical Outcomes of Diabetic Macular Edema Patients Treated with Faricimab and Aflibercept: A Subcohort Analysis of 20/50 or Worse Visual Acuity Across Faricimab Phase 3 Clinical Trials
Zarbin M, Ding A, Tabano D, Ahmed A, Yang M, Evolo V, Stoilov I, Amador M
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:27 AM
Duration 4mins Fontainebleau
Visual Function Loss in Geographic Atrophy (GA): Learnings from Lampalizumab Trial Data
Chakravarthy U, Anegondi N, Steffen V, Ferrara D
Ophthalmology | Geographic Atrophy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:01 AM
Duration 9mins Fontainebleau
Improved Retina Fluid Control With Faricimab vs Aflibercept in Phase 3 Trials in nAMD and DME
Dhoot D, Haskova Z, Ives J, Kotecha A, Margaron P, Souverain A, Tang Y, Willis J
Ophthalmology | Diabetic Macular Edema - Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:37 AM
Duration 9mins Fontainebleau
Individualized Faricimab Dosing up to Q16W Controls Anatomic Outcomes and Maintains Vision Through 2 Years in Age-Related Macular Degeneration (nAMD): Representative Case Studies
Bakri S, Pearce I, Figueroa M, Silverman D, Swaminathan B, Willis J, Kotecha A
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:42 AM
Duration 9mins Fontainebleau
Port Delivery System With Ranibizumab in Diabetic Macular Edema: Primary Analysis Results of the Phase 3 Pagoda Trial
Campochiaro P, Malhotra V, Quezada-Ruiz C, Gune S, DeGraaf S, Bobbala A, Rabena M, Latkany P, Khanani A
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:51 AM
Duration 9mins Fontainebleau
Port Delivery System With Ranibizumab in the Treatment of Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema: Primary Analysis Results of the Phase 3 Pavilion Trial
Holekamp N, Latkany P, Brittain C, Quezada-Ruiz C, Howard D, Santhanakrishnan A, Wetzel-Smith M, Malhotra V, Pieramici D
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:33 PM
Duration 4mins Fontainebleau
Faricimab Causes Rapid and Sustained Intraocular Suppression of Ang-2 and VEGF-A for up to 16 weeks in nAMD and DME
Cheung G, Avery R, Bogman K, Stoilov I, Diack C
Ophthalmology | Diabetic Macular Edema - Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.